Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to drugs related to medical health, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
Beijing Genecradle Therapeutics Co., Ltd. (hereinafter referred to as "Genecradle") has independently developed China's first AAV intrathecal gene therapy drug for Type 1 SMA, the GC101 adeno-associated virus injection, which has passed the first phase of safety evaluation in its registrational clinical trial and is currently ongoing.Phase II Registrational Clinical TrialPatient Recruitment.
The Phase II pivotal clinical trial will be led by the Seventh Medical Center of the Chinese People's Liberation Army General Hospital, with multi-center recruitment taking place at Peking University First Hospital, Shengjing Hospital of China Medical University, and Children's Hospital Affiliated to Shandong University.24-30 namesEligible pediatric subjects with Type 1 SMA, see the table below for details:GC101 Shows Good Safety in SMA Clinical TrialsThe IND registration clinical trial for GC101 injection has been initiated at multiple research centers, including the Seventh Medical Center of the General Hospital of the People's Liberation Army, Peking University First Hospital, Shengjing Hospital of China Medical University, Children's Hospital Affiliated to Shandong University, and Wuhan Children's Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology. Currently, the study includes 11 Type 1 SMA patients and 29 Type 2 SMA patients who have received one-time gene therapy with GC101 injection. Existing data demonstrate the favorable safety and preliminary efficacy of GC101 injection, with the treated young patients showing varying degrees of improvement in motor function.Recruitment Information for Type 3 SMA Clinical Trial RegistrationOn May 6, 2024, the registration clinical trial (acceptance number CXSL2300035) for GC101 injection to treat Type 3 SMA has been approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University, the leading institution. The recruitment of participants will soon be initiated by the leading institution. Please stay tuned for further information.About Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a hereditary neuromuscular disease caused by mutations in the survival motor neuron 1 (SMN1) gene, leading to defective SMN protein function. It is one of the autosomal recessive genetic diseases that cause infant mortality. The carrier frequency of the disease-causing gene in the Chinese population is approximately 1/42, with an incidence rate of about 1/10,000 in newborns. Type 1 SMA presents with significant muscle weakness at birth or within days after birth, and symptoms become quite apparent by 6 months of age. Infants with reduced muscle tone and reflexes experience difficulties in sucking, swallowing, and breathing. Most patients with Type 2 SMA lose the ability to sit independently during adolescence and become paralyzed, often dying from complications such as respiratory failure. Patients with Type 3 SMA are affected in their normal lives by factors such as long-term medication use and the gradual loss of motor function. Among the classifications of SMA, Type 1 SMA is the most severe. Without timely and effective treatment, the median survival time is 13.6 months, with the vast majority not surviving beyond 24 months, making it the leading genetic cause of death in infants.About GC101 Adeno-Associated Virus InjectionGC101 Adeno-Associated Virus Injection is a recombinant adeno-associated virus serotype 9 vector (rAAV9) carrying the normal SMN1 gene expression cassette. Administered as a single dose via intrathecal injection, it enables the expression of the SMN1 gene in motor neurons, thereby improving the function of affected cells such as motor neurons. Combined with respiratory and motor rehabilitation training, it can enhance the respiratory and motor abilities of SMA patients.Beijing Genecradle Therapeutics Co., Ltd. is a national high-tech enterprise with the core business of developing gene therapy drugs mediated by AAV vector delivery technology. Relying on Genecradle’s AAV gene delivery technology platform, Genecradle has developed multiple gene therapy drug pipelines, including treatments for Spinal Muscular Atrophy (SMA), Hypertriglyceridemia, Pompe Disease, and Familial LCAT Deficiency. The selection of these gene drug research directions follows an inherent logic and represents their respective fields.
